Molecular Classification of Endometrial Carcinomas: Review and Recent Updates

Area of Science:

• Gynecologic Oncology
• Cancer Genomics
• Molecular Pathology

Background:

• Endometrial carcinoma (EC) is a leading cause of gynecologic cancer mortality.
• Traditional histology for EC has limitations in predicting prognosis and treatment response due to variability.
• Understanding EC's molecular heterogeneity is crucial for advancing patient care.

Purpose of the Study:

• To review the genomic landscape of endometrial carcinoma.
• To highlight the significance of molecular classification in EC.
• To emphasize the role of molecular biomarkers in personalized therapy.

Main Methods:

• Review of current evidence on EC genomic alterations.
• Analysis of The Cancer Genome Atlas (TCGA) project findings.
• Synthesis of molecular subtypes and their clinical implications.

Main Results:

• The Cancer Genome Atlas (TCGA) identified four distinct EC molecular subtypes: POLE ultra-mutated, microsatellite instability hypermutated (MSI-H), copy number low (CNL), and copy number high (CNH).
• These subtypes exhibit unique genomic profiles, histopathologic features, and clinical behaviors.
• Molecular classification correlates with differential patient outcomes and treatment responses.

Conclusions:

• Molecular classification of EC significantly improves diagnostic accuracy and prognostic stratification.
• Personalized therapy based on molecular subtypes holds promise for optimizing clinical outcomes.
• Further research into molecular biomarkers is essential for refining EC patient management.